Research Paper Volume 12, Issue 22 pp 23200—23216

Development and validation of a nomogram with an epigenetic signature for predicting survival in patients with lung adenocarcinoma

Figure 5. Validation of the epigenetic biosignature in the test set. (A) Rankings for the risk signature and group distribution. (B) Heatmap of the gene-expression profiles. Patients in the high-risk group demonstrated (C) earlier mortality and (D) earlier relapse. (E) OS and (F) RFS of patients in the low- and high-risk groups. ROC analyses of (G) OS and (H) RFS predictions using the epigenetic signature.